Freeline scores $80m Series C
UK-based Freeline, a developer of curative gene therapies for chronic systemic diseases, has raised $80 million in Series C funding.
UK-based Freeline, a developer of curative gene therapies for chronic systemic diseases, has raised $80 million in Series C funding.
Copyright PEI Media
Not for publication, email or dissemination